United States — Food and Drug Administration & Philip Kim
10 shared events · Importance 6 · Last updated May 12, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Disc Medicine, Inc. for its bitopertin program, citing uncertainties in the new drug application.
Philip Kim: Philip Kim is an attorney at Rosen Law Firm and is listed as a contact for investors interested in joining the class action against Disc Medicine, Inc.
May 01, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of tabelecleucel's Biologics License Application due to manufacturing issues is a key factor in the lawsuit against Atara Biotherapeutics.
Philip Kim: Philip Kim is an attorney at Rosen Law Firm, involved in the class action lawsuit against Atara Biotherapeutics.
Apr 01, 2026 · 58 articles
NEWSDESK
Explore this relationship live
Track how United States — Food and Drug Administration and Philip Kim interact across events, view sentiment trends, and discover connected entities.
Open Dashboard